Bacteria-triggered reactive arthritis: Implications for antibacterial treatment

Drugs

Volumn 61, Issue 3, 2001, Pages 343-351

  Toivanen, A ^a  

^a TURKU UNIVERSITY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTRIAXONE; CEFUROXIME; CINOXACIN; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; LYMECYCLINE; MINOCYCLINE; NORFLOXACIN; PENICILLIN G; PIVAMPICILLIN; PIVMECILLINAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALAZOSULFAPYRIDINE; TETRACYCLINE;

ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; BORRELIA BURGDORFERI; CLINICAL TRIAL; HUMAN; LYME DISEASE; PATHOGENESIS; REACTIVE ARTHRITIS; REITER SYNDROME; REVIEW; RHEUMATIC FEVER; SHORT COURSE THERAPY;

BACTERIA (MICROORGANISMS); BORRELIA; BORRELIA BURGDORFERI; POSIBACTERIA;

EID: 0035060467     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161030-00003     Document Type: Review

References (66)

1. Two forms of reactive arthritis?
2. Aetiopathogenesis of reactive arthritis
3. Yersinia-specific immune complexes in the synovial fluid of patients with Yersinia-triggered reactive arthritis
4. Bacterial antigens in synovial biopsy specimens in yersinia-triggered reactive arthritis
5. Yersinia antigens in synovial-fluid cells from patients with reactive arthritis
6. Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression
7. Reiters syndrome and reactive arthritis: A current view
8. Chlamydial rRNA in the joints of patients with chlamydia-induced arthritis and undifferentiated arthritis
9. Chlamydial isolations and serology in Reiter's syndrome
10. Isolation of bedsoniae from the joints of patients with Reiters syndrome
11. Salmonella-triggered reactive arthritis: Use of polymerase chain reaction, immunocytochemical staining, and gas chromatography-mass spectrometry in the detection of bacterial components from synovial fluid
12. Detection of Salmonella infantis in synovial fluid cells of a patient with reactive arthritis
13. Pathogenesis of Yersinia-triggered reactive arthritis: Immunological, microbiological and clinical aspects
14. Persistence of Yersinia enterocolitica in man
15. Clinically silent infections in patients with oligoarthritis: Results of a prospective study
16. Reiter's syndrome: A follow-up study
17. The natural history of reactive arthritis
18. Ten-year follow-up study of patients with Yersinia arthritis
19. Long term prognosis of reactive salmonella arthritis
20. The gut and reactive arthritis
21. Different course of reactive arthritis in two HLA-B27 positive brothers with fatal outcome in one
22. Occurrence of different ensuing triggering infections preceding reactive arthritis: A follow up study
23. Acute rheumatic fever or post-streptococcal reactive arthritis: A clinical problem revisited
24. A clinical and serological comparison of group A versus non-group A streptococcal reactive arthritis and throat culture negative cases of post-streptococcal reactive arthritis
25. Poststreptococcal reactive arthritis: Clinical characteristics and association with HLA-DR alleles
26. Acute rheumatic fever in West Virginia: Not just a disease of children
27. Acute rheumatic fever
28. Acute rheumatic fever in adults: A resurgence in the Hasidic Jewish community
29. Group a streptococcal infections and acute rheumatic fever
30. Long-term outcome of patients with rheumatic fever receiving benzathine penicillin G prophylaxis every three weeks versus every four weeks
31. Post-streptococcal reactive arthritis: A clinical and serological description, revealing its distinction from acute rheumatic fever
32. Prevention of Lyme disease after tick bites
33. Clinical management of Lyme borreliosis
34. Immune responses to Borrelia burgdorferi in patients with reactive arthritis
35. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis
36. Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis
37. Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles
38. Influence of antibiotics on IgA and IgG response and persistence of Yersinia enterocolitica in patients with Yersinia-associated spondylarthropathy
39. Early antibiotic treatment of reactive arthritis associated with enteric infections: Clinical and serological study
40. Reactive arthritis after Salmonella among medical doctors: Study of an outbreak
41. Reactive arthritis following an outbreak of Salmonella bovismorbificans infection
42. A prospective study of Reiter's syndrome: An interim report on the first 82 cases
43. Should we treat postvenereal Reiters syndrome by antibiotics?
44. Antibiotic treatment of venereal disease and Reiter's syndrome in a Greenland population
45. Minocycline in the treatment of patients with Reiter's syndrome
46. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis
47. The anticollagenolytic potential of lymecycline in the long-term treatment of reactive arthritis
48. A double-blind, placebo-controlled comparison of 2 weeks versus 4 months treatment with doxycycline in Chlamydia-induced reactive arthritis
49. Chlamydia trachomatis can persist in joint tissue after antibiotic treatment in chronic Reiters syndrome/reactive arthritis
50. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis
51. Effect of antimicrobial treatment on chronic reactive arthritis
52. Effect of a three-month course of ciprofloxacin on the outcome of reactive arthritis
53. Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis
54. Treatment of reactive arthritis with antibiotics
55. Ankylosing spondylitis: Current approaches to treatment
56. HLA-B27 related arthritis and bowel inflammation. Part 1. Sulphasalazine (Salazopyrin) in HLA-B27 related reactive arthritis
57. Sulphasalazine (Salazopyrin) in the treatment of enterogenic reactive synovitis and ankylosing spondylitis with peripheral arthritis
58. Sulphasalazine in the treatment of reactive arthritis
59. Successful treatment of human immunodeficiency virus-associated Reiters syndrome with sulfasalazine
60. Limited effect of sulphasalazine treatment in reactive arthritis: A randomised double-blind placebo-controlled trial
61. Comparison of sulphasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A Department of Veterans Affairs cooperative study
62. Protective effects of ciprofloxacin against type II collagen induced arthritis in rats
63. Yersinia-associated arthritis in the rat: Experimental model for human reactive arthritis?
64. Long term follow up of SHR rats with experimental yersinia-associated arthritis
65. Antibiotic prophylaxis and treatment of reactive arthritis. Lessons from an animal model
66. Experimental Yersinia-triggered reactive arthritis; effect of a 3-week course with ciprofloxacin